What Documentation Supports an Ozempic Gastroparesis Injury Claim?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Occupational Exposure

The legacy domain of general health and science information has historically provided accessible, structured public data on wellness topics, drawing from sources such as government health portals and academic repositories. This foundation supports broad public understanding of medical conditions and treatments. Transitioning to the target query, the focus shifts to occupational exposure concerns within mass production environments, where workers may encounter pharmaceutical compounds like semaglutide during manufacturing or handling. Documentation for an Ozempic gastroparesis injury claim in this context requires evidence of exposure history, including workplace logs, material safety data sheets, and incident reports. Additionally, medical records documenting gastroparesis diagnosis and its temporal link to exposure are critical. The bridge from general health to occupational exposure emphasizes the need for precise documentation that connects workplace conditions to specific health outcomes, without delving into mechanistic claims. This pivot maintains a neutral, evidence-based approach, leveraging the legacy domain’s emphasis on structured data while addressing the specialized requirements of injury claims in mass production settings.

Clinical Presentation and Diagnosis of Gastroparesis

The clinical presentation of gastroparesis involves delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis is typically confirmed through gastric emptying scintigraphy, breath tests, or wireless motility capsule studies, with objective evidence of retained gastric contents. In the context of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes, the pharmacology of this drug class includes slowing of gastric motility as a mechanism to reduce postprandial glucose excursions. This effect is mediated through GLP-1 receptors in the gastrointestinal tract, which inhibit antral contractions and pyloric relaxation, thereby delaying gastric emptying. The mechanistic pathway linking Ozempic to gastroparesis involves sustained pharmacological inhibition of gastric motility, which can become clinically significant in susceptible individuals, leading to symptomatic gastroparesis that may persist beyond the intended therapeutic window.

Evidence from FDA Adverse Event Reporting System (FAERS)

Documentation supporting an Ozempic gastroparesis injury claim must establish a causal relationship between exposure to the drug and the development of gastroparesis. The FDA Adverse Event Reporting System (FAERS) database provides substantial evidence of this association. As of the most recent data, FAERS reports most frequently associated with Ozempic include "IMPAIRED GASTRIC EMPTYING" with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This term is a direct clinical correlate of gastroparesis. Additionally, the database lists other gastrointestinal adverse events commonly linked to gastroparesis, such as nausea (8,652 reports), vomiting (5,578 reports), diarrhea (5,274 reports), constipation (3,859 reports), dyspepsia (1,374 reports), and abdominal distension (1,408 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). These reports collectively indicate a pattern of gastrointestinal dysfunction consistent with gastroparesis.

Clinical Trial Data from Ozempic Prescribing Information

The Ozempic prescribing information from the DailyMed label further documents gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently at the higher dose (34.0% vs. 30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also lists specific gastrointestinal adverse reactions with frequencies below 5%, including dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the label does not explicitly list "gastroparesis" as a separate adverse reaction, the reported symptoms and the known pharmacological effect of delayed gastric emptying provide a basis for the claim.

Legal Considerations and Documentation for Attorneys

Regarding the adequacy of warnings, the Ozempic label does not include a specific warning for gastroparesis. The gastrointestinal adverse reactions are described in the prescribing information, but the term "gastroparesis" is not used. This may be considered an inadequate warning for patients who develop this condition, as the label does not clearly communicate the risk of persistent gastric emptying impairment that could lead to clinical gastroparesis. For attorney-related considerations, affected patients should document the timeline between Ozempic exposure and the onset of gastroparesis symptoms. The FAERS data and clinical trial evidence indicate that gastrointestinal adverse reactions often occur during dose escalation, but symptoms can persist or develop later. Patients should maintain records of prescription dates, dosage changes, symptom onset, diagnostic tests (e.g., gastric emptying studies), and medical evaluations. Legal claims may focus on failure to warn, as the label does not specifically mention gastroparesis despite the known mechanism and reported adverse events. The timeline between exposure and documented harm is critical. Clinical trial data show that gastrointestinal adverse reactions are most common during dose escalation, but the FAERS data include reports of impaired gastric emptying that may occur at any time during treatment. For a successful claim, plaintiffs must demonstrate that gastroparesis developed after starting Ozempic and that other causes (e.g., diabetes-related autonomic neuropathy, prior surgery, or other medications) were ruled out. The mechanistic pathway—delayed gastric emptying due to GLP-1 receptor agonism—supports a causal link, especially when symptoms appear shortly after dose increases or initiation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the most important documentation for an Ozempic gastroparesis claim?

The most critical documentation includes medical records confirming a gastroparesis diagnosis via gastric emptying scintigraphy or similar tests, prescription records showing Ozempic use, and a timeline linking symptom onset to drug exposure. Additionally, FAERS adverse event reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC) and clinical trial data from the label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) provide supporting evidence of the association.

Does the Ozempic label warn about gastroparesis?

No, the Ozempic label does not specifically warn about gastroparesis. It lists gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but does not use the term 'gastroparesis' or explicitly warn about persistent gastric emptying impairment. This omission may form the basis of a failure-to-warn claim.

How can FAERS data support an Ozempic gastroparesis claim?

FAERS data show 2,693 reports of 'impaired gastric emptying' associated with Ozempic (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC), which is a direct correlate of gastroparesis. These reports, along with high numbers of nausea, vomiting, and other GI symptoms, establish a pattern of gastrointestinal dysfunction consistent with gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.